

ROCC Stars Research on Care Community



Tomorrow's Doctors, Tomorrow's Cures®

Recent Publications

Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak.

Sheng ZM, Chertow DS, Am-broggio X, McCall S, Przygodzki RM, Cunningham RE, Maximova OA, Kash JC, Morens DM, Taubenberger JK. Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16416-21. Epub 2011 Sep 19

Million Veteran Program: A mega-biobank to study genetic influences on health and disease.

Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, Whitbourne S, Deen J, Shannon C, Humphries D, Guarino P, Aslan M, Anderson D, LaFleur R, Hammond T, Schaa K, Moser J, Huang G, Muralidhar S, Przygodzki R, O'Leary TJ J Clin Epidemiol. 2016 Feb;70:214-23

Anatomic and Clinical Pathology Board Review

Ahmed AA, Przygodzki RM, Editors, Wolters Kluwer – Lippincott Williams & Wilkins, Philadelphia, 2017

Ronald M. Przygodzki, MD

Ronald M. Przygodzki, M.D. holds a degree in medicine from the Medical University of Warsaw, Poland. He is board certified in anatomic and clinical pathology (American Board of Pathology), with subspecialization in molecular genetic pathology (American Board of Pathology and American Board of Medical Genetics). He has over 25 years of research and clinical experience with over 15 years of administrative experience.

He is Director of Genomic Medicine Implementation, and Associate Director of the Genomic Medicine Program, Office of Research and Development at the US Department of Veterans Affairs (VA). His previous leadership roles (private and public sectors) include being Director, Biomedical Laboratories

R&D at the VA, as Chief of Pathology at the Children's National Medical Center, and as Associate Director of the Molecular Diagnostics Laboratory at the Armed Forces Institute of Pathology, all in Washington, DC. He conceptualized, drafted and guided implementation of the Million Veteran Program, one of the largest mega-biobanks worldwide.

Dr. Przygodzki's research expertise and interests are in anatomic and clinical pathology and molecular genomics, spanning from the theoretical to practical clinically translatable arenas. He has developed unique molecular-based techniques—in particular, ones invented around the use of small archival tissue specimens typically found in pathology. He has authored numerous publications, book chapters, and books. Some of his molecular pathology research efforts led to the reclassification of two pulmonary malignancies by the World Health Organization, and have allowed him to receive national and international recognition. His current aims are targeting pharmacogenomic combinatorial analyses to help guide opioid and major depression therapies.



Director, Genomic
Medicine Implementation
Associate Director, Genomic Medicine
VA Office of Research & Development